Search

Displaying results 5951 - 5960 of 10000 in total
  1. Drug

    TOP-1288

    go.drugbank.com/drugs/DB14839
    Investigational

    TOP-1288 is under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis

  2. Drug

    Tifcemalimab

    go.drugbank.com/drugs/DB18914
    Investigational

    Tifcemalimab is under investigation in clinical trial NCT06095583 (Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell

  3. Drug

    2-(1-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-4-sulfanyl-3-piperidinylidene) acetic acid

    go.drugbank.com/drugs/DB19221
    Investigational

    2-(1-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-4-sulfanyl-3-piperidinylidene) acetic acid is under investigation in clinical trial NCT03774394 (Impact of Chronic Kidney Disease on Clopidogrel Effects in

  4. Drug

    IMM-0306

    go.drugbank.com/drugs/DB19309
    Investigational

    IMM-0306 (bispecific antibody-trap selectively targeting cd47 and cd20) is under investigation in clinical trial NCT05805943 (Study of IMM0306 in Patients With Relapsed or Refractory Cd20-positive B-cell

  5. Drug

    Lufotrelvir

    go.drugbank.com/drugs/DB16514
    Investigational

    on preprint servers[L31733, L31125]. … Phase 1b studies are also exploring the safety and tolerability of PF-07304814 in COVID-19 patients who are hospitalized (NCT04535167).

  6. Drug

    Tesevatinib

    go.drugbank.com/drugs/DB11973
    Investigational

    Tesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. … In a broad array of preclinical tumor models including breast, lung, colon and prostate cancer, XL647 demonstrated potent inhibition of tumor growth and causes tumor regression.

  7. Drug

    Aprobarbital

    go.drugbank.com/drugs/DB01352
    ExperimentalIllicit

    It was determined that the substance was capable of demonstrating sedative, hypnotic, and anticonvulsant effects. A primary treatment indicated for the use of aprobarbital was subsequently insomnia.

  8. Drug

    QS-21

    go.drugbank.com/drugs/DB05400
    Investigational

    It is the leading member of the Stimulon family of adjuvants. As a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas by Antigenics.

  9. Drug

    Oxogluric acid

    go.drugbank.com/drugs/DB08845
    InvestigationalNutraceutical

    Several experimental studies have also shown that administration of oxogluric acid helped attenuate the decreased synthesis of muscle protein that is often seen post-surgery. … Physiologically, oxogluric acid acts in the Krebs cycle as an intermediate, is involved in transamination reactions during the metabolism of amino acids, forms glutamic acid by combining with ammonia,

  10. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. … It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.